BREDT DAVID (Chief Scientific Officer) sold 2.1% of their position (8.50K shares) of RAPPORT THERAPEUTICS, INC. on the open market
Open‑market sale worth $246.7K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 2/19/2026ACC: 0001193125-26-059883
Officer· Chief Scientific Officer
Since Feb 2026
-8.50K
Net shares
Net seller
$246.7K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
6K acquired · 14.50K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−900.00
Price / share
$28.02
Trade value
$25.22K
% of position
0.2%
2/17/2026
395.57K→394.68K
Common Stock
Direct
Shares
−5.40K
Price / share
$28.95
Trade value
$156.33K
% of position
1.4%
2/17/2026
394.68K→389.27K
Common Stock
Direct
Shares
−2.20K
Price / share
$29.59
Trade value
$65.11K
% of position
0.6%
2/17/2026
389.27K→387.07K
Common Stock
Direct
Shares
+6K
Price / share
$1.80
Trade value
$10.80K
% of position
1.6%
2/19/2026
387.07K→393.07K
Total
Net shares
−2.50K
Net value
-$235.86K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/17/2026 | S · Sale | −900.00 | $28.02 | $25.22K | 0.2% | 395.57K | 394.68K |
| Common Stock Direct | 2/17/2026 | S · Sale | −5.40K | $28.95 | $156.33K | 1.4% | 394.68K | 389.27K |
| Common Stock Direct | 2/17/2026 | S · Sale | −2.20K | $29.59 | $65.11K | 0.6% | 389.27K | 387.07K |
| Common Stock Direct | 2/19/2026 | M · Option Exercise | +6K | $1.80 | $10.80K | 1.6% | 387.07K | 393.07K |
| Total | −2.50K | -$235.86K | ||||||
Derivative Transactions1
Stock Options (Right to Buy)
Direct
Converts to
Common Stock
6K shares
Shares
−6K
Strike price
1.8
Held after
88.08K
Exercisable
—
2/19/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) Direct | Common Stock6K shares | 2/19/2026 | M · Option Exercise | −6K | 1.8 | — | 88.08K |